Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-08-23
2011-08-23
Yu, Misook (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S138100, C424S181100, C530S387300, C530S387700, C530S391100, C530S391700
Reexamination Certificate
active
08003098
ABSTRACT:
The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.
REFERENCES:
patent: 2005/0260639 (2005-11-01), Nakamura et al.
patent: 2006/0039904 (2006-02-01), Wu et al.
patent: 2007/0253954 (2007-11-01), Nakamura et al.
patent: 2010/0040641 (2010-02-01), Tsunoda et al.
patent: WO 95/28484 (1995-10-01), None
patent: WO 03/009814 (2003-02-01), None
patent: WO 2004/031412 (2004-04-01), None
patent: WO 2005/048917 (2005-06-01), None
patent: WO 2005/083086 (2005-09-01), None
patent: WO 2006/047639 (2006-05-01), None
Ashida, S., et al., “Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer: Genome-wide Gene-expression Profiles of Prostate Cancers and PINs,”Cancer Research, vol. 64(17), pp. 5963-5972 (Sep. 1, 2004).
Dottori, M., et al., “EphA4 (Sekl ) receptor tyrosine kinase is required for the development of the corticospinal tract,”Proc. Natl. Acad. Sci. USA, vol. 95(22), pp. 13248-13253 (Oct. 27, 1998).
Iiizumi, M., et al., “EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth,”Cancer Sci., vol. 97(11), pp. 1211-1216 (Nov. 2006, Epub Sep. 5, 2006).
Irving, et al., “Progressive Spatial Restriction ofSek-1andKrox-20Gene Expression during Hindbrain Segmentation,”Developmental Biology, vol. 173(1), pp. 26-38 (Jan. 10, 1996).
Yao, V., et al., “Targeting Pancreatic Islets with Phage Display Assisted by Laser Pressure Catapult Microdissection,”American Journal of Pathology, vol. 166(2), pp. 625-636 (Feb. 17, 2005).
Carles-Kinch, et al.; “Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior;”Cancer Research; 62(10): 2840-2847 (May 2002).
Coffman, et al.; “Differential EphA2 Epitope Display on Normal versus Malignant Cells;”Cancer Research; 63(22):7907-7912 (Nov. 2003).
Dodelet, Vincent C. and Elena B. Pasquale; “Eph receptors and ephrin ligands: embryogenesis to tumorigenesis;”Oncogene; 20(19):5614-5619 (Nov. 2000).
Kullander, Klas and Rüdiger Klein; “Mechanisms and Functions of Eph and Ephrin Signalling;”Nature Review: Molecular Cell Biology; 3(7):475-486 (Jul. 2002).
Kullander, et al.; “Kinase-Dependent and Kinase-Independent Functions of EphA4 Receptors in Major Axon Tract Formation In Vivo;”Neuron; 29(1):73-84 (Jan. 2001).
Murai, Keith K. and Elena B. Pasquale; “‘Eph’ective signaling; forward, reverse and crosstalk;”Journal of Cell Science; 116(Pt. 14):2823-2832 (Jul. 2003).
Hiroshima Shinichi
Kishi Yoshiro
Kuhara Motoki
Nakatsuru Shuichi
Nishida Shiyo
Duffy Brad
Kilpatrick Townsend and Stockton LLP.
Oncotherapy Science, Inc.
Yu Misook
LandOfFree
Methods for damaging cells using effector functions of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for damaging cells using effector functions of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for damaging cells using effector functions of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740775